Selumetinib
Sign in to save this workspacePrimary targets: MEK1, MEK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.640
CATDS
0.032
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Selumetinib. Strongest target: MEK1 at 54.4% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | MEK1 | 54.4% | 45.6% |
| 2 | MEK2 | 33.0% | 67.0% |
| 3 | SYK | 29.1% | 70.9% |
| 4 | MEKK3 | 26.3% | 73.7% |
| 5 | CK1A1 | 25.8% | 74.2% |
| 6 | AKT3 | 25.5% | 74.5% |
| 7 | ERK1 | 24.5% | 75.5% |
| 8 | STK33 | 22.7% | 77.3% |
| 9 | PRKX | 20.0% | 80.0% |
| 10 | CDK17_CYCLIN_Y(PCTK2) | 18.6% | 81.4% |
| 11 | ALK4_ACVR1B | 17.9% | 82.1% |
| 12 | GLK_MAP4K3 | 17.2% | 82.8% |
| 13 | TYRO3_SKY | 17.1% | 82.9% |
| 14 | CDK1_CYCLIN_A | 16.0% | 84.0% |
| 15 | MEKK6 | 15.9% | 84.1% |
| 16 | NEK9 | 15.7% | 84.3% |
| 17 | EPHA6 | 15.7% | 84.3% |
| 18 | RAF1 | 15.3% | 84.7% |
| 19 | AURORA_A | 15.3% | 84.7% |
| 20 | RIPK4 | 14.2% | 85.8% |
Selectivity landscape
Where Selumetinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Selumetinib.
Annotations
Sign in to read and post annotations.
Loading…